

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

**INSIDE INFORMATION
FILING WITH THE CSRC IN RELATION TO THE
PROPOSED IMPLEMENTATION OF H SHARE
FULL CIRCULATION**

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the “**Company**”) in accordance with Rule 13.09(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to “Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies” (《境內企業境外發行證券和上市管理試行辦法》) issued by the China Securities Regulatory Commission (the “**CSRC**”) on 17 February 2023 with effect on 31 March 2023 and the “Guidelines on Application for ‘Full Circulation’ of Domestic Unlisted Shares of H-share Companies” (《H股公司境內未上市股份申請「全流通」業務指引》) issued by the CSRC on 14 November 2019 and further amended on 10 August 2023 (the “**Guidelines**”) regarding the procedures of application by companies whose H Shares are listed on the Stock Exchange for circulation of domestic unlisted shares (as defined under the Guidelines) on the Stock Exchange.

In view of the Guidelines, the board of directors of the Company (the “**Board**”) is pleased to announce that on 23 September 2026, the Company has submitted a filing application to the CSRC (the “**Application**”) with respect to the conversion of 38,921,690 domestic shares of the Company (the “**Domestic Shares**”) held by certain shareholders of the Company into H shares of the Company (the “**H Shares**”), representing approximately 6.75% of the total issued share capital of the Company as at the date of this announcement (the “**H Share Full Circulation**”).

Upon obtaining all relevant approvals (including the filing with the CSRC and approvals from the Stock Exchange) and having complied with all applicable laws, rules and regulations, such Domestic Shares will be converted into H Shares and the Company will apply to the Stock Exchange for the listing of, and permission to deal in, such H Shares on the Main Board of the Stock Exchange (the “**Conversion and Listing**”).

In accordance with the articles of association of the Company and applicable PRC laws, no general meeting of the Company is required to be convened to approve the H Share Full Circulation and the Conversion and Listing.

As at the date of this announcement, the Company’s Application has not been accepted by the CSRC, and the details of implementation plan of the Conversion and Listing have not been finalized. The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in accordance with the requirements of the Listing Rules as and when appropriate.

The H Share Full Circulation and the Conversion and Listing are subject to other relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
23 September 2026

As at the date of this announcement, the executive Directors are Dr. ZHANG Yingjun, Mr. JIANG Juncai and Mr. ZHANG Zhiyong (employee Director), the non-executive Directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei and Dr. LI Wenjia, and the independent non-executive Directors are Dr. LI Xintian, Dr. MA Dawei, Dr. LIN Aimei and Dr. YE Tao.